To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
A RAST test (short for radioallergosorbent test) is a blood test used to determine what a person is allergic to. This is different from a skin allergy test, which determines allergy by the reaction of a person's skin to different substances. For assessing the presence of specific IgE antibodies, allergy skin testing, when possible, is the preferred method in comparison with various in vitro tests because it is more sensitive and specific, simpler to use, and less expensive (http://www.mayoclinicproceedings.com/inside.asp?AID=3978&UID=). 
Additional recommended knowledge
A RAST test, using a person's extracted blood, detects the amount of IgE that reacts specifically with suspected or known allergens. IgE is the antibody associated with the allergic response: if a person exhibits a high level of IgE directed against pollen, the test may indicate the person is allergic to pollen (or pollen-like) proteins. It is worth noting that a person who has outgrown an allergy may still have a positive IgE years after exposure. Because there are other tests that help with confirmation, results are best interpreted by a doctor.
The RAST was introduced in the 1970's and replaced by a superior test in 1989. Advantages of the new test range from: improved sensitivity without loss of specificity, to excellent reproducibility across the full measuring range of the calibration curve. In general, this method of blood testing (in-vitro, out of body) vs skin-prick testing (in-vivo, in body) has a major advantage: it is not always necessary to remove the patient from an anthihistamine medication regimen, and if the skin conditions (such as eczema) are so widespread that allergy skin testing can not be done, RAST tests don't affect results, it's more invasive (one venipuncture needle versus many skin pricks with a plastic device).
The market-leading RAST methodology was invented and marketed in 1974 by Pharmacia Diagnostics AB, Uppsala, Sweden, and the acronymn RAST is actually a brand name. In 1989, Pharmacia Diagnostics AB replaced it with a superior test named the ImmunoCAP Specific IgE blood test, which literature may also describe as: CAP RAST, CAP FEIA (fluorenzymeimmunoassay), and Pharmacia CAP. A review of applicable quality assessment programs shows that this new test has replaced the original RAST in approximately 80% of the world's commercial clinical laboratories, where specific IgE testing is performed. The newest version, the ImmunoCAP® Specific IgE 0-100, is the only specific IgE assay to receive FDA approval to quantitatively report to its detection limit of 0.1kU/l. This clearance is based on the CLSI/NCCLS-17A Limits of Detection and Limits of Quantitation, October 2004 guideline.
RAST often are used to test for allergies when: • a physician advises against the discontinuation of medications that can interfere with test results or cause medical complications; • a patient suffers from severe skin conditions such as widespread eczema or psoriasis; or • a patient has such a high sensitivity level to suspected allergens that any administration of those allergens might result in potentially serious side effects.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "RAST_test". A list of authors is available in Wikipedia.|